Column Capital Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Column Capital Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10	Closed	-$3K	–	725
2019 Q4	$3K	Buy	+10	New	+$3.45K	﹤0.01%	564

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Column Capital Advisors's ATRA Position: Q1 2020 in Review

Column Capital Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2020, closing a stake of 10 shares — an estimated $3K sold.

Column Capital Advisors first reported a position in ATRA in Q4 2019 and held it in 1 quarter. The position peaked at $3K in Q4 2019. 111 funds tracked by Wall St. Rank hold ATRA as of Q1 2020.

Column Capital Advisors reported no remaining Atara Biotherapeutics position as of Q1 2020 after selling out during the quarter.
Column Capital Advisors sold 10 Atara Biotherapeutics shares in Q1 2020, an estimated $3K.
Column Capital Advisors first reported a position in Atara Biotherapeutics in Q4 2019 and held it in 1 quarter.
Column Capital Advisors's Atara Biotherapeutics position peaked at $3K in Q4 2019.
111 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2020.

Based on Column Capital Advisors's 13F filing for Q1 2020, filed 11 May 2020.